CEBPZ and acute myeloid leukemia: To further investigate whether KIT D816mut/CBFneg defines a distinct AML subtype associated with SM and poor prognosis, two independent AML databases (AMLdatabases, German/Austrian AML Study Group, Munich Leukemia Lab) were retrospectively screened for KIT D816mut/CBFneg AML patients (selection criteria were all AML patients with available status on CBF and KIT D816mut).